Prostaglandin E2 in the expired breath condensate of patients with asthma

European Respiratory Journal

Volumn 22, Issue 5, 2003, Pages 743-747

  Kostikas, K ^a   Papatheodorou, G ^a   Psathakis, K ^a   Panagou, P ^a   Loukides, S ^a,b  

^a 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Asthma; Bronchial hyperresponsiveness; Exhaled breath condensate; Prostaglandin E2

Indexed keywords

BRONCHODILATING AGENT; HISTAMINE; PROSTAGLANDIN E2; STEROID; DIAGNOSTIC AGENT;

ADULT; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION FUNCTION; EXPIRED AIR; FORCED EXPIRATORY VOLUME; HUMAN; PREDICTION; PRIORITY JOURNAL; PROVOCATION TEST; STATISTICAL ANALYSIS; BREATH ANALYSIS; INHALATION TEST; METABOLISM; PATHOPHYSIOLOGY; REPRODUCIBILITY; RESPIRATORY SYSTEM; SMOKING;

ADULT; ASTHMA; BREATH TESTS; BRONCHIAL PROVOCATION TESTS; DINOPROSTONE; FORCED EXPIRATORY VOLUME; HISTAMINE; HUMANS; REPRODUCIBILITY OF RESULTS; RESPIRATORY SYSTEM; SMOKING;

EID: 0242551091     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00000603     Document Type: Article

References (30)

1. 2 regulation of the immune response. Immunol Today 1991; 12: 349-352.
2. 2. Lancet 1994; 344: 436-438.
3. 2 on allergen-induced asthma. Am Rev Respir Dis 1993; 148: 87-90.
4. Pasargiklian M, Bianco C, Allegra L, et al. Aspects of bronchial reactivity to prostaglandins and aspirin in asthmatic patients. Respiration 1977; 34: 79-91.
5. 2a reduce exhaled nitric oxide in normal and asthmatic subjects irrespective of airway caliber changes. Am J Respir Crit Care Med 1998; 158: 1374-1378.
6. Tetsuka T, Morrison AR. Tyrosine kinase activation is necessary for inducible nitric oxide synthase expression by interleukin-1β. Am J Physiol 1995; 269: 55-59.
7. Peters SP, Schulman ES, MacGlashan DW, Schleimer RP, Newball HH, Lichtenstein LM. Pharmacological and biochemical studies of human lung mast cells. J Allergy Clin Immunol 1982; 69: 150-158.
8. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1693-1622.
9. Montuschi P, Barnes PJ. Exhaled leukotrienes and prostaglandins in asthma. J Allergy Clin Immunol 2002; 109: 615-620.
10. Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166: 301-306.
11. Hwang D, Chanmugam P, Boudreau M, Sohn KH, Stone K, Pryor WA. Activation and inactivation of cyclo-oxygenase in rat alveolar macrophages by aqueous cigarette tar extracts. Free Radic Biol Med 1999; 27: 673-682.
12. Global strategy for asthma management prevention. NIH Publication No. 02-3659. Bethesda, MD, National Institutes of Health, National Heart, Lung and Blood Institute, February 2002.
13. Sovijarvi AR, Malberg LP, Reinikminen K, Ryhila Poggins H. A rapid dosimetric method with controlled tidal breathing for histamine challenge. Chest 1993; 104: 164-170.
14. American Thoracic Society official statement. Guidelines for Methacholine and Exercise Challenge Testing - 1999. Am J Respir Crit Care Med 2000; 161: 309-329.
15. Ganas K, Loukides S, Papatheodorou G, Panagou P, Kalogeropoulos N. Total nitrite/nitrate in expired breath condensate of patients with asthma. Respir Med 2001; 95: 649-654.
16. Huszar E, Vass G, Vizi E, et al. Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma. Eur Respir J 2002; 20: 1393-1398.
17. Jobsis Q, Raatgeep HC, Schelleke SL, Hop WCJ, Hermans PW, de Jongste JC. Hydrogen peroxide in exhaled air of healthy children: reference values. Eur Respir J 1998; 12: 483-485.
18. Bland JM, Altman DG. Statistical method for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
19. 2 in rectal mucosa in human subjects: a method study. Cancer Epidemiol Biomarkers Prev 1995; 4: 239-244.
20. O'Byrne P. Prostanoids. In: Barnes PJ, Drazen JM, Rennard S, Thompson NC, eds. Asthma and COPD. San Diego, Academic Press, 2002; pp. 221-226.
21. Pavord ID, Ward R, Woltmann G, Wardlaw AJ, Sheller JR, Dworski R. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med 1999; 160: 1905-1909.
22. Riutta A, Saareks V, Mucha I, Alanko J, Parviainen M, Vapaatalo H. Smoking cessation and nicotine substitution modulate eicosanoid synthesis ex vivo in man. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 102-107.
23. 2 formation by nicotine and cotinine. Pharmacology 1999; 58: 70-86.
24. Barnes PJ, Chung KP, Page PC. Inflammatory mediators of asthma. An update. Pharmacol Rev 1998; 50: 515-596.
25. 2 inhibits acetylcholine release from cholinergic nerves in canine airways. Prostaglandins Leukot Essent Fatty Acids 1994; 51: 347-355.
26. 2 from rat intrapulmonary bronchi. Am J Physiol 1998; 275: 1006-1012.
27. 2 on bronchial reactivity to sodium metabisulphite and metacholine in subjects with asthma. Thorax 1991; 46: 633-637.
28. 2 but not prostacyclin inhibits histamine-induced contraction of human bronchial smooth muscle. Eur J Pharmacol 1995; 272: 13-19.
29. 2) in airways of subjects with asthma. Am J Respir Crit Care Med 2000; 162: 637-640.
30. Bonazzi A, Bolla M, Buccellati C, et al. Effect of endogenous and exogenous prostaglandin E(2) on interleukin-1 beta-induced cyclooxygenase-2 expression in human airway smooth-muscle cells. Am J Respir Crit Care Med 2000; 162: 2272-2277.